Status:
COMPLETED
Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium
Lead Sponsor:
AbbVie
Conditions:
Ankylosing Spondylitis
Psoriatic Arthritis
Eligibility:
All Genders
18-50 years
Brief Summary
This observational study will document to what extent in daily clinical practice the work productivity is affected before and after the start of adalimumab treatment. Changes in the employment status...
Eligibility Criteria
Inclusion
- Patient \>= 18 years and \<= 50 years
- Patient diagnosed with AS or PsA
- Patient to be initiated on adalimumab (according to the Marketing Authorization and Belgian reimbursement criteria)
- Patient willing to sign informed consent
Exclusion
- Any contraindication for adalimumab as specified in the corresponding Summary of Product Characteristics (SmPC)
- Patient previously treated with biologics
- Patient participating in other AbbVie-sponsored trials
Key Trial Info
Start Date :
June 5 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 23 2017
Estimated Enrollment :
183 Patients enrolled
Trial Details
Trial ID
NCT01845818
Start Date
June 5 2013
End Date
June 23 2017
Last Update
January 9 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.